Longeveron Inc. (NASDAQ:LGVN), a biopharmaceutical company specializing in regenerative medicine with a market capitalization of $23.81 million, announced the immediate resignation of Mr. Neil Hare ...
Dr. Roger Hollis from the University of California, Los Angeles, project scientist from the laboratory of Dr. Donald Kohn, a world leader in developing gene replacement therapies using blood stem ...
Theradaptive, a Maryland-based, privately held, clinical-stage biologics company, today announced the initiation of patient dosing in Maryland for the ongoing OASIS Phase I/II clinical trial assessing ...
Jonathan Rigby, President and CEO of Sernova, stated, “We are thrilled to welcome Ross Haghighat as our new Chair of the Board. His deep industry knowledge and visionary leadership make him the ...